Core Viewpoint - Heng Rui Medicine (01276) has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, Zemeituosita Tablets (SHR2554), aimed at adult patients with relapsed or refractory peripheral T-cell lymphoma (R/RPTCL) who have previously undergone at least one line of systemic therapy [1] Group 1: Company Developments - Heng Rui Medicine's stock rose over 3%, specifically by 3.21%, reaching HKD 82.05 with a trading volume of HKD 206 million [1] - Zemeituosita Tablets is the first self-developed EZH2 inhibitor in China, marketed under the name Airiqing [1] - The drug effectively inhibits both wild-type and mutant EZH2 enzyme activity, reactivating tumor suppressor genes and improving the tumor microenvironment [1] Group 2: Research and Development - The total R&D investment for Zemeituosita Tablets has reached approximately RMB 213 million [1]